Kromek Share Discussion Threads

[aqc888] 20/5/2022 08:11

If having lots of irons in lots of fires is what you’re after investing in Augmentum fintech or Frontier IP fits the bill a whole load better - with track records of success - not failure

[slicethepie] 19/5/2022 10:22

Kmk have lots of irons in lots of fires let's hope one gets hot! ALL IMO DYORSP

[strategicinvestor2] 19/5/2022 08:38

hxxps://www.kromek.com/news/rethinking-our-readiness-whitepaper-authored-by-experts-in-the-field/

[strategicinvestor2] 18/5/2022 14:33

Very frustrating on pathogen detectors - we are told revolutionary world first any pathogen detector working with DARPA… hopefully some positive news flow on this soon ………; use on crops etc hopefully we don’t have to wait until year end results

[aqc888] 18/5/2022 11:50

The ceo said a while back they were in “serious discussions with multiple governments” regarding the detector. Yet a few days ago they say that £4m of future revenue is in negotiations. Doesn’t add up. To network a country would cost £1bn the ceo stated. Multiple government discussions amount to £4m we learned a few days ago. Doesn’t add up in the slightest. But nothing coming out of their mouths ever does add up… £10m from China order… ventilators etc

[strategicinvestor2] 18/5/2022 11:41

One of the main appeals for me is that incremental revenues are at a c.48% gross margin so scope for rapid growth in profits with a bit of revenue….

[robertsjj] 18/5/2022 11:03

The pathogen detector was explicitly mentioned in the prospectus accompanying the open offer/firm placing in Feb. Therefore, it was subject to aim rule 10. It is worrying that they now seem to be washing their hands of any mention of the detector. They must have spent the money on developing it - unless they broke the Aim Rules. Why would they now not mention it when sales to China could be booming? ST also no mention of the April deadline… IMO DYOR

[strategicinvestor2] 17/5/2022 01:24

Is it likely to also make the printed version of IC and if so when is it published? Readership copies c30,000 I think.

Am disappointed with managements lack of update of pathogen detection but hopefully means commercial discussions in progress but who knows !!??

[slicethepie] 16/5/2022 21:35

Onwards and upwards!ALL IMO DYORSP

[strategicinvestor2] 16/5/2022 20:39

Thanks for the update. I see he is forecasting a 48% rise in revenue to £18m and cash profitability going forward. I would hope for a lot more than this !!

[aqc888] 16/5/2022 19:07

Just been re-tipped as a ‘recovery buy’ in investors chronicle by Simon Thompson

[aqc888] 16/5/2022 14:25

Another £30k from the chairman is a good sign, but it’s not an amount that gets me interested in buying any. If a director invested £100k+ of their own money this week, it would certainly get my attention and make many reassess Kromek.

37% of forward revenue is in negotiations. So no hope of any big bio detector sales at present.

[dougmachin] 16/5/2022 13:22

30,011 UKP's worth of good Ali.

[ali47fish] 16/5/2022 12:59

this might be good



16 May 2022



Kromek Group plc

("Kromek" or the "Group")



Director Share Purchase



Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that Rakesh Sharma, Non-Executive Chairman, has today purchased 338,344 ordinary shares of 1 pence each in the Group ("Ordinary Shares") at a price of 8.87 pence per Ordinary Share.



Following this purchase, Mr Sharma has an interest in 807,539 Ordinary Shares, representing 0.19% of the issued share capital of the Group.

[quepassa] 16/5/2022 12:24

the new broker will be pulling out all the stops and more to get the price moving up sharpish - and they will likely have said that they have access to new and additional investors to tap into.

today's results aren't moving the price but the new Research from the new broker is.

The old broker had been a long-standing and loyal supporter of Kromek - it must have been something pretty compelling to get Kromek to switch horses.

I guess it's not too difficult to figure out what.



Just seen the first of the announcements orchestrated to shift the price up. A £30k purchase of shares by the Chairman.



The share price is being driven up.

For investors - fundamentals haven't changed.
For traders - a great short-term opportunity.


ALL IMO. DYOR.
QP

[strategicinvestor2] 16/5/2022 12:24

NED director £30,000 purchase…..

[strategicinvestor2] 16/5/2022 12:17

Any one access this report on explosive detection market growth. Views on this research from reviewing the detailed analysis?

hxxps://www.digitaljournal.com/pr/explosive-detection-technologies-market-growth-analysis-2022-industry-size-global-share-top-manufacturers-safran-smiths-l-3-communications-kromek-business-revenues-impact-of-covid-19-region

[strategicinvestor2] 16/5/2022 12:11

The all pathogen detector is the global game changer IMHO DYOR

[ark87] 16/5/2022 12:05

Looks to me the covid detector either flat out doesn’t work well enough to be viable or there is simply no interest.

and for those who believe KMK will never do another equity raise with their track record are kidding themselves. Anytime KMK come out of their shell is shortly followed by begging for more money and huge dilution.

[strategicinvestor2] 16/5/2022 11:44

Looks like strong move to positive EBITDA next year and cash net operating generation IMHO DYOR

[charlie_bucket] 16/5/2022 11:24

I believe cash of £5.1m mentioned is gross cash. Net cash after deducting borrowings will be lower, maybe even negative. Borrowings were £6.8m in the interims, and cash was £10.2m.

Does look to me like shareholder money is being spent on research papers in getting that share price up so that they can get shares away without being hugely diluting. And with no directors using their own money to buy shares to try and have the same effect. Say they want to raise £15m plus fees. Current market cap is £35m at price of 8 pence. That’s 200 million new shares, nearly half as many as now in issue!

I think existing and new shareholders need to be careful. Despite the technology and products’ potential and the progress being made, I believe this can still go down further and even to zero if they can’t raise more equity capital particularly if the overall market has a sharp downturn. Ask yourself: are the same institutions who bought in at 15 pence last time going to double down and buy more at a lower share price when they are holding a loss in these market conditions? Has what the company said last time come true? Or are the institutions going to invest elsewhere?

Another point is that I believe a “clean” audit report for the year end accounts without a “going concern” qualification would depend on new equity funding being in place to guarantee trading for the 12 months after the issue of the annual accounts later this year.

All just my opinions, need to do your own research and come to your own.

[strategicinvestor2] 16/5/2022 11:05

Interesting medium term target of 40p…

[dougmachin] 16/5/2022 10:35

Not worth selling now IMO. From that report:

- Valuation. The strategic value of Kromek as the only independent supplier of CZT will not be captured in a multiples-based approach. We therefore value Kromek using a sum-of-the-parts approach and introduce a 12-month valuation of £118m (implying c.27p), but can see how this can move up towards 40p. Catalysts for this increase include contract wins, particularly a second major medical imaging contract and for further radiation detectors.